Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma

References

• Akao T, Kimura T, Hirofuji Y-S, et al. (2010). A poly(gamma-glutamic acid)-amphiphile complex as a novel nanovehicle for drug delivery system. J Drug Target 18:550–6
   PubMed Web of Science ®Google Scholar
• Alexander-Bryant AA, Dumitriu A, Attaway CC, et al. (2015). Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo. J Control Release 218:72–81
   PubMed Web of Science ®Google Scholar
• Benjamin GD, Robinson MA. (2002). Drug delivery systems based on sugar macromolecule conjugates. Curr Opin Drug Discov Dev 5:279–88
   PubMedGoogle Scholar
• Bertinchant JP, Polge A, Juan JM, et al. (2003). Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 329:39–51
   PubMed Web of Science ®Google Scholar
• Beuth J, Ko HL, Oette K, et al. (1987). Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and D-galactose. J Cancer Res Clin Oncol 113:51–5
   PubMed Web of Science ®Google Scholar
• Bialecki ES, Di Bisceglie AM. (2005). Diagnosis of hepatocellular carcinoma. HPB 7:26–34
   PubMedGoogle Scholar
• Chen L, Liu Y, Wang W, Liu K. (2015). Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy. Oncol Lett 10:77–84
   PubMed Web of Science ®Google Scholar
• Derajram MBM, Devarajan PV (2015). In situ lipidization as a new approach for the design of a self microemulsifying drug delivery system (SMEDDS) of doxorubicin hydrochloride for oral administration. J Biomed Nanotechnol 11:913–22
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Devarajan PV. (2015a). Asialoglycoprotein receptor mediated hepatocyte targeting – strategies and applications. J Control Release 203:126–39
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Devarajan PV. (2015b). Hepatic targeting – addressing vital therapeutic needs. Indian Drugs 52:7–15
   Google Scholar
• D’Souza AA, Devarajan PV. (2016). Bioenhanced oral curcumin nanoparticles: role of carbohydrates. Carbohydr Polym 136:1251–8
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Jain P, Galdhar CN, et al. (2013). Comparative in silico–in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin gantrez nanoparticles. AAPS J 15:696–706
   PubMed Web of Science ®Google Scholar
• Eisinger-Mathason TS, Karin M, Zhang Q, et al. (2013). Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov 3:1190–205
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–76
   PubMed Web of Science ®Google Scholar
• Guhagarkar SA, Gaikwad RV, Samad A, et al. (2010). Polyethylene sebacate – doxorubicin nanoparticles for hepatic targeting. Int J Pharm 401:113–22
   PubMed Web of Science ®Google Scholar
• Guhagarkar SA, Malshe VC, Devarajan PV. (2009). Nanoparticles of polyethylene sebacate: a new biodegradable polymer. AAPS PharmSciTech 10:935–42
   PubMed Web of Science ®Google Scholar
• Guo S, Michael Lin C, Xu Z, et al. (2014). Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996–5009
   PubMed Web of Science ®Google Scholar
• Ha SY, Choi M, Lee T, Park C-K. (2016). The prognostic role of mitotic index in hepatocellular carcinoma patients after curative hepatectomy. Cancer Res Treat 48:180–9
   PubMed Web of Science ®Google Scholar
• Han JH, Oh YK, Kim DS, Kim CK. (1999). Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. Int J Pharm 188:39–47
   PubMed Web of Science ®Google Scholar
• Huang G, Diakur J, Xu Z, Wiebe LI. (2008). Asialoglycoprotein receptor-targeted superparamagnetic iron oxide nanoparticles. Int J Pharm 360:197–203
   PubMed Web of Science ®Google Scholar
• Jain A, Jain K, Mehra NK, Jain NK. (2013). Lipoproteins tethered dendrimeric nanoconstructs for effective targeting to cancer cells. J Nanopart Res 15:2003
   Web of Science ®Google Scholar
• Joshi VM, Devarajan PV. (2014). Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand. Drug Deliv Transl Res 4:353–64
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26:492–501
   PubMed Web of Science ®Google Scholar
• Kaneo Y, Ueno T, Tanaka T, et al. (2000). Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. Int J Pharm 201:59–69
   PubMed Web of Science ®Google Scholar
• Kato T, Date T, Miyamoto M, et al. (2005). Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79:592–6
   PubMed Web of Science ®Google Scholar
• Khandekar SV, Kulkarni MG, Devarajan PV. (2014). Polyaspartic acid functionalized gold nanoparticles for tumor targeted doxorubicin delivery. J Biomed Nanotechnol 10:143–53
   PubMed Web of Science ®Google Scholar
• Kumar CS, Raja MD, Sundar DS, et al. (2015). Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydr Polym 128:63–74
   PubMed Web of Science ®Google Scholar
• Langeswaran K, Gowtham Kumar S, Perumal S, et al. (2013). Limonin – a citrus limonoid, establish anticancer potential by stabilizing lipid peroxidation and antioxidant status against N-nitrosodiethylamine induced experimental hepatocellular carcinoma. Biomed Prev Nutr 3:165–71
   Google Scholar
• Li Y, Huang G, Diakur J, Wiebe LI. (2008). Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 5:299–302
   PubMedGoogle Scholar
• Long J-T, Cheang T-Y, Zhuo S-Y, et al. (2014). Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnol 12:37
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Aukerman SL, Polin L, et al. (1990). Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res 50:5876–82
   PubMed Web of Science ®Google Scholar
• Lu C, Xing MM, Zhong W. (2011). Shell cross-linked and hepatocyte-targeting nanoparticles containing doxorubicin via acid-cleavable linkage. Nanomed Nanotechnol Biol Med 7:80–7
   PubMed Web of Science ®Google Scholar
• Manil L, Couvreur P, Mahieu P. (1995). Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharm Res 12:85–7
   PubMed Web of Science ®Google Scholar
• Manil L, Davin JC, Dechenne C, et al. (1994). Uptake of nanoparticles by rat glomerular mesangial cells in vitro and in vivo. Pharm. Res 11:1160–5
   Google Scholar
• Manka SW, Carafoli F, Visse R, et al. (2012). Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci USA 109:12461–6
   PubMed Web of Science ®Google Scholar
• McAbee DD, Jiang X, Walsh KB. (2000). Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor’s lectin properties. Biochem J 348:113–17
   PubMed Web of Science ®Google Scholar
• Mezghrani O, Tang Y, Ke X, et al. (2015). Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Int J Pharm 478:553–68
   PubMed Web of Science ®Google Scholar
• Neijzen R, Wong MQ, Gill N, et al. (2015). Irinophore CTM, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. J Control Release 199:72–83
   PubMed Web of Science ®Google Scholar
• Poelstra K, Prakash J, Beljaars L. (2012). Drug targeting to the diseased liver. J Control Release 161:188–97
   PubMed Web of Science ®Google Scholar
• Pranatharthiharan S, Patel MD, Malshe VC, Devarajan PV. (2016). Polyethylene sebacate doxorubicin nanoparticles: role of carbohydrate anchoring on in vitro and in vivo anticancer efficacy. Drug Deliv 1–10
   PubMed Web of Science ®Google Scholar
• Prescott JH, Enriquez P, Jung C, et al. (1995). Larch arabinogalactan for hepatic drug delivery: isolation and characterization of a 9 kDa arabinogalactan fragment. Carbohydr Res 278:113–28
   PubMed Web of Science ®Google Scholar
• Pütz G, Schmider W, Nitschke R, et al. (2005). Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J Lipid Res 46:2325–38
   PubMed Web of Science ®Google Scholar
• Rekha MR, Sharma CP. (2011). Hemocompatible pullulan-polyethyleneimine conjugates for liver cell gene delivery: in vitro evaluation of cellular uptake, intracellular trafficking and transfection efficiency. Acta Biomater 7:370–9
   PubMed Web of Science ®Google Scholar
• Sagnella SM, McCarroll JA, Kavallaris M. (2014). Drug delivery: beyond active tumor targeting. Nanomed Nanotechnol Biol Med 10:1131–7
   PubMed Web of Science ®Google Scholar
• Sattler FR, Paolucci S, Kreider JW, Ladda RL. (1982). A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice. Eur J Cancer Clin Oncol 18:381–9
   PubMedGoogle Scholar
• Schwartzs AL, Fridovich SE, Lodish HF. (1982). Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem 257:4230–7
   PubMed Web of Science ®Google Scholar
• Shah SM, Goel PN, Jain AS, et al. (2014). Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand. Int J Pharm 477:128–39
   PubMed Web of Science ®Google Scholar
• Shen Z, Wei W, Tanaka H, et al. (2011). A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacol Res 64:410–19
   PubMed Web of Science ®Google Scholar
• Shete H, Sable S, Tidke P, et al. (2015). Mono-guanidine heterolipid based SMEDDS: a promising tool for cytosolic delivery of antineoplastics. Biomaterials 57:116–32
   PubMed Web of Science ®Google Scholar
• Shingel KI. (2004). Current knowledge on biosynthesis, biological activity, and chemical modification of the exopolysaccharide, pullulan. Carbohydr Res 339:447–60
   PubMed Web of Science ®Google Scholar
• Shinoda T, Maeda A, Kagatani S, et al. (1998). Specific interaction between galactose branched-cyclodextrins and hepatocytes in vitro. Int J of Pharm 167:147–54
   Web of Science ®Google Scholar
• Tanaka T, Fujishima Y, Hamano S, Kaneo Y. (2004). Cellular disposition of arabinogalactan in primary cultured rat hepatocytes. Eur J Pharm Sci 22:435–44
   PubMed Web of Science ®Google Scholar
• Torosean S, Flynn B, Axelsson J, et al. (2013). Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomed Nanotechnol Biol Med 9:151–8
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Sadeghi H, et al. (2013). Retinoic acid decorated albumin-chitosan nanoparticles for targeted delivery of doxorubicin hydrochloride in hepatocellular carcinoma. J Nanomater 2013:Volume Article ID 254127, 12 pages
   Web of Science ®Google Scholar
• Vincenz L, Jager R, O’Dwyer M, Samali A. (2013). Endoplasmic reticulum stress and the unfolded protein response: targeting the achilles heel of multiple myeloma. Mol Cancer Therap 12:831–43
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen H, Liu Y, et al. (2013). pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. Biomaterials 34:7181–90
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Liu Y, et al. (2015). A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. Int J Pharm 483:89–100
   PubMed Web of Science ®Google Scholar
• Wartha K, Herting F, Hasmann M. (2014). Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation. Pharmacol Therap 142:351–61
   PubMed Web of Science ®Google Scholar
• Wei M, Xu Y, Zou Q, et al. (2012). Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 46:131–41
   PubMed Web of Science ®Google Scholar
• Xin YF, Zhou GL, Deng ZY, et al. (2007). Protective effect of Lycium barbarum on doxorubicin-induced cardiotoxicity. Phytother Res 21:1020–4
   PubMed Web of Science ®Google Scholar
• Yan M, Li H, Zhao F, et al. (2013). Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissue. Chin J Cancer Res 25:289–98
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang W, Liu T, et al. (2012). Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials 33:2187–96
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu J, Fai Chan H, et al. (2016). iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomed Nanotechnol Biol Med 12:1303–11
   PubMed Web of Science ®Google Scholar
• Zhang X, Helena Ng HL, Lu A, et al. (2016). Drug delivery system targeting advanced hepatocellular carcinoma: current and future. Nanomed Nanotechnol Biol Med 12:853–69
   PubMed Web of Science ®Google Scholar
• Zhang Y, He J, Cao D, et al. (2014). Galactosylated reduction and pH dual-responsive triblock terpolymer Gal-PEEP-a-PCL-ss-PDMAEMA: a multifunctional carrier for the targeted and simultaneous delivery of doxorubicin and DNA. Polym Chem 5:5124–38
   Web of Science ®Google Scholar
• Zinkin NT, Grall F, Bhaskar K, et al. (2008). Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 14:470–7
   PubMed Web of Science ®Google Scholar
• Zou Y, Song Y, Yang W, et al. (2014). Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J Control Release 193:154–61
   PubMed Web of Science ®Google Scholar